Jubilant Pharmova is looking to raise roughly ₹1,400 crore (about $150 million) through a rupee-denominated debt offering, according to bankers and business reporting. The plan involves the sale of three-year bonds with bullet maturity.
Both outlets describe the same fundraising approach—using short-term, fixed terms rather than longer-dated securities—though they do not add further details in the information provided. Business Line emphasises the target size in both rupees and dollars and notes bankers’ expectations regarding the deal structure. The Economic Times uses similar framing focused on the dollar figure and the rupee debt sale, presenting it as a straightforward funding move by the company.
No additional information is provided here on proceeds’ use, coupon rates, investor demand, or regulatory approvals, so those elements remain unspecified across the sources.